Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2 single-arm study of intrathecal GC101 in infants with spinal muscular atrophy type 1
ChiCTR2200056833Phase 2Completed
- Sponsor
- Seventh Medical Center of the People's Liberation Army General Hospital
- Start
- Jan 2022
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nolgileucel in spinal muscular atrophy type 1, sponsored by Seventh Medical Center of the People's Liberation Army General Hospital. Primary endpoints: Adverse events at Day 364 and Laboratory examination at Day 364. Started Jan 2022; status: completed.
02
Drugs
nolgileucel
03
Conditions
spinal muscular atrophy type 1
Beyond the preview
Go deeper on ChiCTR2200056833.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200056833.